COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS
CollPlant Biotechnologies (NASDAQ: CLGN), a company specializing in regenerative and aesthetics medicine with a focus on non-animal-derived rhCollagen technology, has announced it will release its first quarter 2025 financial results on Wednesday, May 28, 2025, before U.S. markets open. The company develops innovative technologies and products for tissue regeneration and medical aesthetics applications.
CollPlant Biotechnologies (NASDAQ: CLGN), un'azienda specializzata in medicina rigenerativa ed estetica con un focus sulla tecnologia rhCollagen di origine non animale, ha annunciato che pubblicherà i suoi risultati finanziari del primo trimestre 2025 mercoledì 28 maggio 2025, prima dell'apertura dei mercati statunitensi. L'azienda sviluppa tecnologie e prodotti innovativi per la rigenerazione dei tessuti e applicazioni di medicina estetica.
CollPlant Biotechnologies (NASDAQ: CLGN), una empresa especializada en medicina regenerativa y estética con un enfoque en la tecnología rhCollagen de origen no animal, ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el miércoles 28 de mayo de 2025, antes de la apertura de los mercados estadounidenses. La compañía desarrolla tecnologías y productos innovadores para la regeneración de tejidos y aplicaciones en medicina estética.
CollPlant Biotechnologies (NASDAQ: CLGN)는 동물 유래가 아닌 rhCollagen 기술에 중점을 둔 재생 및 미용 의학 전문 회사로, 2025년 1분기 재무 결과를 2025년 5월 28일 수요일 미국 시장 개장 전에 발표할 예정이라고 밝혔습니다. 이 회사는 조직 재생 및 의료 미용 분야를 위한 혁신적인 기술과 제품을 개발합니다.
CollPlant Biotechnologies (NASDAQ : CLGN), une entreprise spécialisée dans la médecine régénérative et esthétique avec un accent sur la technologie rhCollagen d'origine non animale, a annoncé qu'elle publiera ses résultats financiers du premier trimestre 2025 le mercredi 28 mai 2025, avant l'ouverture des marchés américains. La société développe des technologies et des produits innovants pour la régénération des tissus et les applications en médecine esthétique.
CollPlant Biotechnologies (NASDAQ: CLGN), ein Unternehmen, das sich auf regenerative und ästhetische Medizin mit Schwerpunkt auf nicht-tierischer rhCollagen-Technologie spezialisiert hat, gab bekannt, dass es seine Finanzergebnisse für das erste Quartal 2025 am Mittwoch, den 28. Mai 2025 vor Öffnung der US-Märkte veröffentlichen wird. Das Unternehmen entwickelt innovative Technologien und Produkte für die Geweberegeneration und medizinische Ästhetikanwendungen.
- None.
- None.
REHOVOT,
About CollPlant
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com
Contacts:
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: +972-73-2325600
Email: eran@collplant.com
Investors:
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-date-for-first-quarter-financial-results-302455030.html
SOURCE CollPlant
FAQ
When will CollPlant Biotechnologies (CLGN) report Q1 2025 earnings?
What is CollPlant Biotechnologies' (CLGN) main business focus?
What stock exchange is CollPlant Biotechnologies (CLGN) listed on?
What type of collagen technology does CollPlant (CLGN) use?
